|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Alza Corporation, DE, USA |
|---|---|
| Information provided by: | Alza Corporation, DE, USA |
| ClinicalTrials.gov Identifier: | NCT00424931 |
Purpose
The purpose of this study is to evaluate the safety and effectiveness of JNJ-17216498 compared to modafinil and placebo in patients with narcolepsy, with and without cataplexy.
| Condition | Intervention | Phase |
|---|---|---|
|
Narcolepsy |
Drug: JNJ-17216498 Drug: Modafinil |
Phase II |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Parallel Assignment, Safety/Efficacy Study |
| Official Title: | A Phase II Randomized, Double-Blind, Double-Dummy, Placebo and Comparator-Controlled, Parallel Group, Multi-Center Study to Investigate the Safety and Efficacy of a Single Dose of JNJ-17216498 Administered to Subjects With Narcolepsy. |
| Enrollment: | 65 |
| Study Start Date: | November 2006 |
| Study Completion Date: | December 2007 |
| Primary Completion Date: | November 2007 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| 001: Experimental |
Drug: JNJ-17216498
10mg one time
|
| 002: Experimental |
Drug: JNJ-17216498
50mg one time
|
| 003: Active Comparator |
Drug: Modafinil
200 mg X 2
|
This study with a new, experimental drug is being done to assess safety and tolerability, and to explore effectiveness in the treatment of narcolepsy. Approximately 64 adult patients with narcolepsy with or without cataplexy will be recruited for the study. Patients who meet study criteria will need to stop taking their current narcolepsy and/ or other medication for at least 14 days before checking into the site for 3 nights. They will be randomly assigned to one of 4 treatment arms; each patient has an equal chance of receiving placebo, 10 mg JNJ-17216498, 50 mg JNJ-17216498 or 400 mg modafinil. Placebo has no active drug. Modafinil is a drug currently approved to treat narcolepsy. Patients will take the medication on only one day and will receive study medication in a blinded fashion, i.e. the patient, the doctor and the study sponsor will not know what group the patient is in until all patients complete the study. The investigator and the sponsor will monitor the study for the occurrence of possible side effects. In addition to a screening visit and the three nights at the site, there will be a follow-up visit 7-10 days after the day the study drug is taken. After the follow-up visit, patients may resume their previous narcolepsy medications. Medical history, physical examination, vision tests, blood pressure, heart rate, temperature, and ECGs will be checked periodically. Blood samples will be taken for standard safety laboratory tests as well as for the measurement of the drug blood level. The Maintenance of Wakefulness Test will be done to assess the patient's ability to resist falling asleep while reclining in a dark, quiet room; this will involve completing 7 sessions before dosing and 10 sessions after dosing. Patients will have two polysomnograms, a test of brain, muscle and eye activity during sleep, obtained by recording brain waves and other activities such as muscle and eye movement. Polysomnograms will be obtained overnight, once before and once after dosing. Patients will also complete brief questionnaires about their sleepiness and the status of their narcolepsy throughout the study.
Patients will receive capsules containing either 10 mg JNJ-17216498, 50 mg JNJ-17216498, 400 mg modafinil and/or placebo on one day. Seven capsules will be taken orally in the morning and two capsules will be taken orally in the afternoon. Placebo contains no active drug. Modafinil is a drug currently approved to treat narcolepsy.
Eligibility| Ages Eligible for Study: | 18 Years to 55 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations
More Information
| Responsible Party: | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. ( Clinical Leader ) |
| Study ID Numbers: | CR013390, C-2006-028 |
| Study First Received: | January 19, 2007 |
| Last Updated: | April 2, 2009 |
| ClinicalTrials.gov Identifier: | NCT00424931 History of Changes |
| Health Authority: | United States: Food and Drug Administration |
|
sleepiness narcolepsy |
|
Nervous System Diseases Physiological Effects of Drugs Dyssomnias Sleep Disorders Central Nervous System Stimulants Disorders of Excessive Somnolence Protective Agents Neuroprotective Agents |
Modafinil Pharmacologic Actions Sleep Disorders, Intrinsic Narcolepsy Mental Disorders Therapeutic Uses Central Nervous System Agents |